Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2409021 Formulations in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy males or surgically sterile or postmenopausal females, as determined by medical history and physical examination~* Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m\^2)~* Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator~Exclusion Criteria:~* Have known allergies to LY2409021, related compounds or any components of the formulation, or history of significant atopy~* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have known or ongoing psychiatric disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Part A: LY2409021 Capsule (Type: EXPERIMENTAL): Single oral dose of LY2409021 capsule in one of three study periods.
- Part A: LY2409021 Tablet Pre-commercial (Type: EXPERIMENTAL): Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
- Part A: LY2409021 Tablet Commercial (Type: EXPERIMENTAL): Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
- Part B: LY2409021 Capsule (Type: EXPERIMENTAL): Single oral dose of LY2409021 capsule in one of two study periods.
- Part B: LY2409021 Tablet Commercial (Type: EXPERIMENTAL): Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).